2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Fostemsavir (FTR): Oral HIV Attachment Inhibitor

• Prodrug of temsavir: binds to gp120, inhibits HIV attachment to CD4 • Phase 3 trial in heavily treatment experiencedpatients with virologic failure (BRIGHTE)

• Randomized- 272 pts with ≥1 fully activedrug in 1 or 2 classes. 8 days blinded therapy (FTR or pbo), then FTR + OBT

• Non-Randomized- 99 pts with no fully

activeapproved drug. FTR + OBT

Lataillade, IAS2019.MOAB0102

Slide25of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

BRIGHTE: Most Common ARVs in Initial Optimized Background Therapy (OBT)

Slide credit: clinicaloptions.com

Lataillade. IAS2019.AbstrMOAB0102.Reproducedwithpermission.

Slide26of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

BRIGHTE: ITT-E Virologic Response Through Wk 96

Slide27of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Slidecredit: clinicaloptions.com